Anzeige
Mehr »
Freitag, 29.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PBYQ | ISIN: US29350E1047 | Ticker-Symbol: 2Q5
Tradegate
27.08.25 | 20:33
0,210 Euro
-3,67 % -0,008
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RENOVARO INC Chart 1 Jahr
5-Tage-Chart
RENOVARO INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2070,21816:39
0,2070,21816:37
ACCESS Newswire
269 Leser
Artikel bewerten:
(1)

Renovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors

LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a leading journal in the field of immunology. The paper details compelling preclinical data on Renovaro's next-generation dendritic cell (DC) therapy platform, showcasing its ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models.

The published study, titled "Therapeutic Efficacy of CD34-derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer," represents a major milestone in validating the scientific underpinnings of Renovaro's platform. The therapy combines cutting-edge genetic engineering with an allogeneic "off-the-shelf" approach to generate highly potent DCs capable of priming the immune system against aggressive, immunoresistant tumors.

"This publication marks a critical moment for Renovaro," said David Weinstein, Renovaro's CEO. "The data clearly demonstrate the potential of our engineered dendritic cell therapy to overcome tumor-induced immunosuppression, which is one of the greatest challenges in treating pancreatic and other solid tumors. It further validates the broader capabilities of our cell engineering platform."

Key Findings from the Study Include:

  • Robust Anti-Tumor Efficacy: Engineered DCs expressing CD93, CD40L, and CXCL13 significantly reduced tumor weight and volume, namely up to 81.7% in humanized mouse models.

  • Immune Activation: Treated animals showed marked increases in CD4? T cells as well as cytotoxic CD8? T and NK cells in blood, bone marrow, and tumor microenvironments.

  • Antigen-Specific Response: Activated T cells demonstrated selective cytotoxicity against pancreatic tumor cells while sparing unrelated cell types.

  • Scalable, Off-the-Shelf Platform: The use of CD34? hematopoietic stem cells from healthy donors enables scalable production and cryopreservation of engineered DCs, enhancing clinical utility.

This research builds on Renovaro's broader strategy of developing immune-enhancing therapies that can be flexibly adapted for solid tumor indications and lays the foundation for future AI-based antigen discovery that will further specialize these medications toward specific cancer indications and patient sub-populations. The engineered DC platform complements Renovaro's growing pipeline of precision medicines.

"By demonstrating not only efficacy but also scalability and specificity, this work strengthens our competitive moat and reaffirms our position as a platform company built to deliver durable impact," added Dr. Lu Chen, Renovaro's Executive Vice President of Product Development and CMC.

Renovaro plans to initiate additional preclinical studies across multiple tumor types and explore combination strategies with checkpoint inhibitors and radioligand therapies. These efforts are part of a broader roadmap to bring this novel therapeutic platform into the clinic.

This work was performed in collaboration with immunology professor Dr. Anahid Jewett, who sadly passed away last month. Her exceptional guidance and unique expertise allowed this project to progress, and the acceptance of this publication serves as further testament to her extraordinary ability as a researcher.

The full peer-reviewed article is available via Vaccines: https://www.mdpi.com/2076-393X/13/7/749

About Renovaro Biosciences

Renovaro (NASDAQ: RENB) is a TechBio company combining advanced machine learning with breakthrough immunotherapies to transform how cancer and other diseases are detected and treated. Through proprietary platforms in cell therapy, RNA diagnostics, and federated AI, Renovaro is pioneering scalable and personalized approaches to precision medicine.

Contact:

David Weinstein
Chief Executive Officer
investors@renovaro.com
www.renovarogroup.com

SOURCE: Renovaro Biosciences



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/peer-reviewed-study-validates-renovaros-genetically-engineered-dendritic-cell-therapy-1049730

© 2025 ACCESS Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.